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http://www.biomedcentral.com/1471-2407/14/71RESEARCH ARTICLE Open AccessThe novel arylindolylmaleimide PDA-66 displays
pronounced antiproliferative effects in acute
lymphoblastic leukemia cells
Christin Kretzschmar1†, Catrin Roolf1†, Tina-Susann Langhammer1, Anett Sekora1, Anahit Pews-Davtyan2,
Matthias Beller2, Moritz J Frech3, Christian Eisenlöffel3, Arndt Rolfs3,4 and Christian Junghanss1*Abstract
Background: Prognosis of adult patients suffering from acute lymphoblastic leukemia (ALL) is still unsatisfactory.
Targeted therapy via inhibition of deregulated signaling pathways appears to be a promising therapeutic option for
the treatment of ALL. Herein, we evaluated the influence of a novel arylindolylmaleimide (PDA-66), a potential
GSK3β inhibitor, on several ALL cell lines.
Methods: ALL cell lines (SEM, RS4;11, Jurkat and MOLT4) were exposed to different concentrations of PDA-66.
Subsequently, proliferation, metabolic activity, apoptosis and necrosis, cell cycle distribution and protein expression
of Wnt and PI3K/Akt signaling pathways were analyzed at different time points.
Results: PDA-66 inhibited the proliferation of ALL cells significantly by reduction of metabolic activity. The 72 h
IC50 values ranged between 0.41 to 1.28 μM PDA-66. Additionally, caspase activated induction of apoptosis could
be detected in the analyzed cell lines. PDA-66 influenced the cell cycle distribution of ALL cell lines differently. While
RS4;11 and MOLT4 cells were found to be arrested in G2 phase, SEM cells showed an increased cell cycle in
G0/1 phase.
Conclusion: PDA-66 displays significant antileukemic activity in ALL cells and classifies as candidate for further
evaluation as a potential drug in targeted therapy of ALL.
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Acute lymphoblastic leukemia (ALL) is characterized by
a poor prognosis in adult patients with a general survival
rate of 27 to 54% [1]. In recent years targeted thera-
peutic approaches such as Imatinib or Rituximab have
been developed and implemented successfully in the
treatment [2-4]. However, despite of these implementa-
tions the prognosis of adult patients remains poor indi-
cating the need for further research in order to identify
and evaluate new potential drugs targeting deregulated
signaling pathways.* Correspondence: christian.junghanss@med.uni-rostock.de
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distribution, and reproduction in any mediumArylindolylmaleimides are a group of synthetic mole-
cules characterized by the conjunction of a maleimide
compound with a bicyclic indole ring and a further aro-
matic structure. PDA-66 is an analogue of the arylindo-
lylmaleimide SB-216763 and was newly synthesized as
described by Pews-Davtyan et al. [5]. Both compounds
possess similar structural features, but differ in their
substitution pattern (Figure 1). In comparison to SB-
216763, in PDA-66 the indolyl group is characterized by
an unprotected 2-methylindole unit, while the malei-
mide group is methylated. Notably, the 2,4-dichloro sub-
stitution pattern is replaced with 4-acetyl group.
Concerning functional activity SB-216763 was shown to
inhibit the enzyme activity of Glycogen Synthase Kinase
3β (GSK3β) by 96% at a concentration of 10 μM (IC50:
34.3 nM) in an ATP competitive manner [6] leading tontral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Structural formula of SB-216763 and PDA-66.
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also be mediated by GSK3β inhibition.
GSK3β is a highly activated serine/threonine kinase in
resting cells with normal metabolism [7]. Besides its in-
fluence on the glycogen synthesis GSK3β is involved
in Wnt/β-catenin and Phosphatidylinositole 3 kinase
(PI3K)/Akt signaling antagonizing cell growth and cell
cycle progression in both pathways. However, inhibition
of GSK3β led to decreased cell growth and increased
apoptosis in different tumor cell lines as glioblastoma
cells [8], gastrointestinal cancer cells [9,10], ovarian cancer
cells [11], medullary thyroid cancer cells [12], pancreatic
cancer cells [13] and primary pediatric ALL cells [14].
Joint previous analyses published by Eisenlöffel et al. [15]
investigated the influence of PDA-66 in human neuronal
progenitor cells (hNPCs) and revealed an inhibitory effect
on proliferation and an increased rate of apoptosis. Fur-
thermore, an antiproliferative impact on human lung can-
cer and glioblastoma cell lines was detected [15].
In this study, we analyzed the biological effects of PDA-
66 on B- and T-ALL cell lines and determined the influ-
ence on kinase activity of human recombinant GSK3β.
Our results show an inhibitory effect on the proliferation
and metabolic activity of ALL cells accompanied by an in-
crease in apoptosis and necrosis rates. Furthermore, a
minor effect on GSK3β activity could be demonstrated
which was not as pronounced as caused by SB-216763.
Methods
Inhibitors
PDA-66 was synthesized at the Leibniz Institute for Ca-
talysis (Rostock, Germany) and kindly provided by the
Albrecht-Kossel-Institute (Rostock, Germany). SB-216763
was purchased from Sigma (Taufkirchen, Germany).
Chemical structures of both substances are displayed in
Figure 1. The substances were dissolved in dimethyl sulf-
oxide (DMSO). The stock solutions (10 mM) were stored
at -20°C. For experimental use the drugs were freshly pre-
pared from stock solution.
Cell lines
The human B-ALL cell lines SEM, RS4;11 and the T-
ALL cell lines Jurkat and MOLT4 were purchased from
DSMZ (Braunschweig, Germany) and cultured accordingto manufacturer’s protocol. The corresponding medium
was supplemented with 10% heat-inactivated fetal bovine
serum (PAA, Pasching, Austria) and 1% penicillin and
streptomycin (Biochrom AG, Berlin, Germany). The
MOLT4 cells were cultured with medium supplemented
with 20% heat-inactivated fetal bovine serum. All cells
were maintained at 37°C in 5% CO2.
Treatment of ALL cell lines with PDA-66
Cells (5x105/well) were seeded in 24 well plates (Nunc,
Langenselbold, Germany) and incubated for up to 72 h
with different concentrations of PDA-66 (0.1 – 10 μM).
Treated cells were harvested after 4, 24, 48 and 72 h and
used for further analyses. Control cells were cultured in
medium containing the same concentration of DMSO as
the cells treated with the highest dose of PDA-66.
Proliferation studies
Cell counts were determined by trypan blue staining.
Metabolic activity was analyzed by tetrazolium com-
pound WST-1 (Roche, Mannheim, Germany). In brief,
triplicates of cells (5x104/150 μl) were seeded in 96 well
plates, treated with different concentrations of PDA-66
and incubated with 15 μl WST-1 for up to 4 h. The
mitochondrial dehydrogenases reduce WST-1 to soluble
formazan and cause a change of color correlating with
the amount of metabolically active cells. Absorbance at
450 nm and a reference wavelength at 620 nm were de-
termined by an ELISA Reader (Anthos, Krefeld,
Germany). The absorbance of culture medium with sup-
plemented WST-1 in the absence of cells was used as
background control.
May-Grünwald Giemsa staining
After treatment with 1 μM PDA-66 glass slides were pre-
pared with 3x104 cells with Cytospin 3 centrifuge (Shandon,
Frankfurt/Main, Germany). Briefly, slides were incubated
6 min in May-Grünwald solution (Merck, Darmstadt,
Germany), washed with tap water, incubated 20 min
in Giemsa solution (Merck, Darmstadt, Germany), and
washed in tap water again. To evaluate morphological
changes of the cells slides were analyzed by Nikon Eclipse E
600 light microscope and imaged with NIS Elements soft-
ware (Nikon, Düsseldorf, Germany).
Analyses of apoptosis and necrosis
Apoptosis and necrosis were analyzed by staining the
cells with Annexin V FITC (BD Biosciences, Heidelberg,
Germany) and Propidium iodide (PI) (Sigma Aldrich, St.
Louis, USA). Results were assessed by flow cytometry.
Briefly, 5x105 cells were harvested and washed twice
(180 g, 10 min, 4°C) with PBS. After resuspending the
cells in 100 μl of binding buffer (1×) 4 μl of Annexin V
FITC was added and incubated for 15 min at room
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binding buffer for a final volume of 500 μl the cells were
stained with PI (0.6 μg/ml) immediately before measure-
ment. Unstained and single stained cells were included
in each experiment as controls. Measurements were per-
formed using FACSCalibur (Becton, Dickinson and
Company, Heidelberg, Germany) and data analyzed by
CellQuest software (Becton, Dickinson and Company,
Heidelberg, Germany).
Cell cycle analysis
After treatment cells were harvested and washed twice
in PBS. Cells were fixed with 70% ethanol and incubated
with 1 mg/ml Ribonuclease A (Sigma-Aldrich, St. Louis,
USA) for 30 min at 37°C. After washing the cells twice
in PBS, they were stained with PI (50 μg/ml) and DNA
content was determined by flow cytometry.
Western blot
Protein extraction and western blot was performed as de-
scribed previously [16]. Following antibodies were used:
rabbit anti-cleaved caspase 3 (5A1E), rabbit anti-caspase 3
(polyclonal), rabbit anti-cleaved PARP (D64E10), rabbit
anti-PARP (polyclonal), rabbit anti-cleaved caspase 7
(polyclonal), rabbit anti-caspase 7 (polyclonal), rabbit anti-
pAktThr308 (polyclonal), rabbit anti-pAktSer473 (poly-
clonal), rabbit anti-Akt (polyclonal), rabbit anti-β-catenin
(6B3), rabbit anti-pGSK3βSer9 (5B3), rabbit anti-GSK3β
(27C10), rabbit anti-p4EBP-1Ser65 (174A9) and rabbit
anti-4EBP-1 (polyclonal) (all Cell Signaling, Frankfurt/
Main, Germany). Blots were incubated with mouse anti-
GAPDH antibody (Invitrogen, Carlsbad, USA) as loading
control.
Kinase activity assay
The kinase activity assay was performed as previously
described [17]. Briefly, 20 ng of recombinant human
GSK3β (Biomol, Hamburg, Germany) were incubated
with the substrate phospho glycogen synthase peptide 2
(pGS2, 25 μM) (Millipore, Billerica, USA), ATP (1 μM)
(Cell Signaling, Frankfurt am Main, Germany) and dif-
ferent concentrations of PDA-66 and SB-216763 for
30 min at 30°C. After addition of Kinase-Glo (Promega,
Mannheim, Germany) and 10 min of incubation at room
temperature the luminescence signal was measured with
a Glomax 96 microplate reader (Promega).
Statistical analysis
Results within each experiment were described using
mean ± standard deviation. Significance between control
and treated cells was calculated using Student’s t-test. A
p-value < 0.05 was considered to be significant. The IC50
values of PDA-66 where determined with SPSS (Version
15) software via probit analysis.Results
PDA-66 inhibits proliferation and metabolic activity of
ALL cells
The influence of PDA-66 on proliferation and metabolic
activity in ALL cell lines SEM, RS4;11, Jurkat and
MOLT4 was analyzed by incubation with different con-
centrations of the drug ranging from 0.1 μM to 10 μM
for 48 and 72 h, respectively (Figure 2). After 48 h incu-
bation an inhibition of proliferation could be observed
(Figure 2A), which was even more distinct after 72 h
(Figure 2B). All cell lines showed a significant dose
dependent inhibition of proliferation starting at a con-
centration of 0.5 μM PDA-66.
Likewise proliferation, metabolic activity decreased
with increasing concentrations of PDA-66. After 72 h of
incubation the metabolic activity was significantly dose
dependent reduced in all cell lines starting at a concen-
tration of 0.5 μM PDA-66 (Figure 2D). At this concen-
tration the metabolic activity decreased to 35.7 ± 8.3% in
SEM, to 33.3 ± 4.4% in RS4;11, to 66.7 ± 8% in Jurkat
and to 35.5 ± 17% in MOLT4 cells compared to control
cells treated with DMSO (= 100%). Furthermore, in
WST-1 assay the IC50 for PDA-66 in all four cell lines
where determined (Table 1). The IC50 values ranged
from 0.41 μM in SEM cells to 1.28 μM in Jurkat cells
after 72 h of incubation.
The incubation of ALL cell lines with higher dosages
of PDA-66 (0.5 μM or more) led to a decrease in cell
numbers below the amount of seeded cells (5x105). This
result indicates besides an inhibition of cell proliferation
also an induction of cell death.
PDA-66 influences morphology as well as cell cycle
progression and induces apoptosis
To evaluate possible morphological changes cells were
treated with 1 μM of PDA-66 for 48 h and analyzed by
light microscopy. All four cell lines showed similar
changes in morphology after PDA-66 treatment com-
pared to DMSO treated control cells. Exemplarily, ef-
fects in SEM and Jurkat cells are shown in Figure 3. In
contrast to DMSO treated control cells the incubation
of 1 μM PDA-66 led to condensation of chromatin in
the nucleus, karyorrhexis and an increasing amount of
vacuoles and cell debris after 48 h of treatment. Conden-
sated chromatin points to an induction of apoptosis or
cell cycle arrest in the analyzed cell lines.
Cell cycle analysis was performed by PI staining and
flow cytometrical measurement. The treatment with
PDA-66 for 48 h influenced the four cell lines in differ-
ent manner (Figure 4). SEM cells showed a significant
increase in the amount of cells in G0/G1 after incuba-
tion with 0.5 μM (DMSO control: 62.8 ± 2.8%; 0.5 μM
PDA-66: 69.3 ± 2.7%) whereas 1 μM did not affect the
cell cycle significantly. RS4;11 and MOLT4 cells were
SEM RS4;11 Jurkat
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Figure 2 Treatment with PDA-66 inhibits cell proliferation and metabolic activity. SEM, RS4;11, Jurkat and MOLT4 cells were incubated with
different concentrations of PDA-66. Metabolic activity was determined using WST-1 assay. The results of optical density measurement were
expressed as a percentage of the DMSO treated control cells. The two upper diagrams show the results of cell count after PDA-66 treatment after
48 h (A) and 72 h (B). The lower diagrams display the influence of PDA-66 on the metabolic activity, respectively (C, D). The proliferation and
metabolic activity of all cell lines was suppressed significantly at higher concentrations. Results are displayed as the mean + SD of three independent
experiments. *Significant treatment effect vs. DMSO control, α = 0.05.
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1 μM PDA-66. The amount of RS4;11 and MOLT4 cells in
G2 phase increased from 20.1 ± 3.9% and 21.9 ± 4.9% after
incubation with DMSO to 42.1 ± 4.4% and 41.0 ± 5.8% after
1 μM PDA-66 treatment. This was associated with a signifi-
cant decrease in G0/G1 phase (RS4;11 and MOLT4: 65.7 ±
2.1% and 63.7 ± 6.6% in control; 47.3 ± 2.7% and 45.0 ±
7.3% after treatment with 1 μM PDA-66). On the other
hand lower concentrations led to significant increase of
cells in G0/G1 phase. Jurkat cells showed a significant de-
crease in G0/G1 phase (from 60.0 ± 3.7% in control to 47.3
± 4.3% with PDA-66) and an increase in S phase (from
14.6 ± 1.5% in control to 20.0 ± 1.1% with PDA-66) after in-
cubation with 1 μM PDA-66. The analyses of cell cycle after
longer incubation intervals interfered with high rates of
apoptosis and necrosis (data not shown).Table 1 IC50 values of PDA-66 in WST-1 assay
IC50 [μM]




MOLT4 2.41 0.52The effect of PDA-66 on apoptosis and necrosis rates
was determined by flow cytometric analysis after 48 and
72 h of incubation and further analysed by western blot
after 24 and 48 h, respectively (Figure 5). After 48 h of
incubation all PDA-66 treated cell lines showed a signifi-
cant increase in apoptosis compared to control cells
(SEM: 2.1 ± 0.9% to 10.5 ± 1.3%; RS4;11: 2.5 ± 0.7% to
7.4 ± 1.1%; Jurkat: 3.8 ± 0.6% to 8.3 ± 1.9%; MOLT4:
3.7 ± 1.2% to 16.3 ± 5.1%). After 72 h a similar ten-
dency could be observed, but only deviations in SEM
and MOLT4 cells where significant (SEM: 1.3 ±
0.4% to 5.6 ± 1.6%; RS4;11: 2.1 ± 0.9% to 6.4 ± 3.6%;
Jurkat: 4.7 ± 1.9% to 6.1 ± 0.7%; MOLT4: 4.9 ± 1.9% to
20.1 ± 6.6%).
All cells showed a non significant increase in necrosis
after 48 and 72 h incubation with 1 μM PDA-66. After
72 h incubation necrosis rate rose in SEM cells from 3.1
± 1.6% to 27.8 ± 5.81%, in RS4;11 cells from 6.1 ± 0.8% to
26.5 ± 10.2%, in Jurkat cells from 5.7 ± 3.5% to 28.0 ±
13.4% and in MOLT4 cells from 11.7 ± 3.6% to 46.7 ±
15.6% (Figure 5A). Analysis via western blot showed an
apoptosis induction in all cell lines. Treatment with
PDA-66 induced cleavage of caspases 3 and 7 and PARP
48 h after addition of PDA-66. In Figure 5B results of
















Figure 3 Light microscopy reveals karyorrhectic morphology after PDA-66 treatment in SEM and Jurkat cells. Cytospins of SEM and Jurkat
cells were stained with Pappenheim method after 48 h incubation with 1 μM PDA-66 and DMSO, respectively. Representative pictures are displayed. The
upper pictures show SEM and Jurkat cells after DMSO treatment, the lower ones show PDA-66 treated cells. After treatment with PDA-66 an increased
amount of cells with chromatin condensation (black arrow a) and karyorrhexis (black arrow b) could be observed along with more cell debris.
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β-catenin
In order to characterize the effects of PDA-66 on PI3K/
Akt and Wnt/β-catenin pathways we performed western










































Figure 4 PDA-66 leads to cell cycle arrest in G2 phase in RS4;11 and
cell cycle distribution was determined using Propidium iodide staining. On
shown for the two B-ALL cell lines SEM and RS4;11. On the right side the res
G2 arrest could be detected in RS4;11 and MOLT4 cells. Treatment of Jurkat cell
Results are displayed as the mean + SD of three independent experiments. *Sigwere shifted to 4 and 24 h as effects on protein level are
expected to be detectable earlier compared to the effects
on the whole cell. The incubation with PDA-66 showed
no detectable influence on the expression of β-catenin,









M 0.5 µM 1 µM
MOLT4 cells. ALL cell lines were incubated for 48 h with PDA-66 and
the left side the amount of cells in the different phases of cell cycle is
ults for the T-ALL cell lines Jurkat and MOLT4 are displayed, respectively.
s induced a decrease of cells in G0/G1 phase in favor of cells in S phase.


















































































Figure 5 Treatment with PDA-66 induces apoptosis via cleavage of caspases. (A) Cells were treated with PDA-66 for up to 72 h and stained
with Annexin V FITC and Propidium iodide (PI). Rates of early apoptotic (FITC+, PI-) and late apoptotic and necrotic (FITC+, PI+) cells were
measured by flow cytometry. The upper diagrams display the rate of apoptotic cells after 48 h (left) and 72 h (right). The lower diagrams show the
results for necrosis measurement, respectively. Significant induction of apoptosis could be observed in all cell lines after 48 h of incubation as well as
tendential induction of necrosis at both points of time. Results are displayed as the mean + SD of three independent experiments. *Significant
treatment effect vs. DMSO control, α = 0.05. (B) Cells were treated with different concentrations of PDA-66 and total cell lysates (25 μg) were analyzed
by Western blot to detect cleavage of Caspase 3, 7 and PARP. GAPDH was used as loading control. Exemplary results of PDA-66 treated SEM cells after
24 and 48 h are displayed. Induction of apoptosis was confirmed by an increase of the cleaved forms of Caspase 3, 7 and PARP.
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be detected in SEM cells after an incubation of 24 h,
though not accompanied by an increase of pAktSer473.
Furthermore, in SEM cells a decrease of pGSK3βSer9
was observed after 4 h. However, no influence on the
total form of β-catenin was detectable. Nevertheless,
there was an influence of PDA-66 on the expression of
4EBP-1 and p4EBP-1Ser65. SEM, RS4;11 and Jurkat cells
showed a decrease of the phosphorylated as well as the
total form of 4EBP-1 after an incubation of 4 and 24 h.
In contrast, MOLT4 cells displayed an increase of the
phosphorylated form at these points of time (Figure 6B).
PDA-66 does not inhibit kinase activity of recombinant
GSK3β as distinct as SB-216763
The effect of PDA-66 on the GSK3β enzyme activity was
determined by incubation with the specific substrate pGS2,
PDA-66 or SB-216763 and ATP. The following addition of
Kinase-Glo reagent converts the remaining ATP into a lu-
minescence signal which correlates with enzyme inhibition.
SB-216763 demonstrated a stable inhibition of GSK3β at
concentrations from 0.1 to 5 μM which was statistically sig-
nificant at 5 μM (Figure 7). Compared to this PDA-66
showed a less pronounced inhibition of enzyme activity at
concentration from 0.1 to 1 μM which were not significant.Discussion
The prognosis of ALL in adult patients is still poor and
requires further research for new therapeutic ap-
proaches. In this study we could demonstrate for the
first time a pronounced antiproliferative effect of the
novel arylindolylmaleimide PDA-66 on different B and T
ALL cell lines. We investigated the influence of PDA-66
on ALL cells in respect of proliferation, metabolic activ-
ity, morphology, apoptosis, cell cycle arrest, and activa-
tion of PI3K/Akt and Wnt/β-catenin signaling pathways.
Furthermore, the effect on kinase activity of GSK3β was
determined.
PDA-66 was recently synthesized and described as an
analogue to SB-216763, which is a known GSK3β inhibi-
tor [6]. The inhibition of this kinase has been extensively
examined in various neoplastic cells types and demon-
strated an attenuated proliferation in malignant cells
[9-14]. Investigating the influence of PDA-66 on the en-
zyme activity of human recombinant GSK3β we found a
minor inhibition in vitro which was much less distinct
and not significant compared to our results obtained
with SB-216763. While the basic molecular structure of
SB-216763 and PDA-66 is the same, both compounds
differ in their substitution patterns. In comparison to












































































Figure 6 PDA-66 does not influence expression of proteins of Wnt/β-catenin pathway but alters expression of 4EBP-1. After treatment
with PDA-66 and DMSO, respectively, cells were lyzed and protein expression analyzed with Western blot. (A) Exemplary results of PDA-66 treated
SEM cells after 4 and 24 h are displayed. No influence on expression of total GSK3β and the total form of Akt could be noticed. PhosphoGSK3βSer9
seemed decreased at higher PDA-66 concentrations after 4 h. No influence on the amount of β-catenin was observed. (B) Exemplary results of SEM,
RS4;11 and MOLT4 cells are displayed. In SEM and RS4;11 cells a decrease of 4EBP-1 and p4EBP-1Ser65 was detectable, in contrast MOLT4 cells showed an


























Figure 7 PDA-66 does not inhibit GSK3β kinase activity.
Recombinant human GSK3β was incubated with pGS2, ATP and different
concentrations of PDA-66 and SB-216763. While treatment with the
known GSK3β inhibitor SB-216763 lead to a stable reduction of enzyme
activity with significant alterations at 5 μM PDA-66 showed only a slight
inhibitory potential. Results are displayed as the mean± SD of five
independent experiments. In each experiment the concentrations of
PDA-66 and the control were tested with 4 replicates. RLU = relative
luminescence units. *Significant treatment effect vs. DMSO control, α = 0.05.
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group. Additionally, the 2,4-dichloro substitution pattern
is replaced with a 4-acetyl group in PDA-66. These
structural changes are supposed to be key in the reduced
capacity of PDA-66 to inhibit GSK3β.
The influence of PDA-66 on GSK3β activity including
other key enzymes of Wnt/β-catenin and PI3K/Akt sig-
naling pathways was also investigated by western blot.
Affirming the results obtained by kinase activity assay,
we found no enhanced activation of the Wnt/β-catenin
pathway. Considering the role of GSK3β in Wnt signal-
ing an increase of β-catenin would have been expected
when inhibiting GSK3β. Furthermore, no effect on the
protein expression of GSK3β and no distinct activation
of Akt were detectable. In the PI3K/Akt signaling path-
way GSK3β acts downstream of Akt [18], although
Takada et al. demonstrated that the TNF induced activity
of Akt is dependent on GSK3β [19], indicating a possible
feedback loop. In the herein analyzed SEM cells a slight
increase in pAktThr308 could be observed. However,
there was no detectable increase in pAktSer473, which is
primarily responsible for activation of Akt [20].
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status and the total amount of protein of 4EBP-1 at 4 and
24 h after treatment. 4EBP-1 is a downstream target of
mTOR, which is inhibited by GSK3β via phosphorylation
of TSC2 [21]. The phosphorylation and concomitant in-
activation of 4EBP-1 by mTOR leads to disaggregation of
4EBP-1 from eIF4F, a translation initiation factor [22].
Walsh and Mohr demonstrated that the phosphorylation
of 4EBP-1 leads to its proteasomal degradation [23]. In
our study the effect of PDA-66 on the amount of 4EBP-1
was ambiguous. SEM, RS4;11 and Jurkat cells displayed a
reduced expression whereas MOLT4 cells showed an en-
hanced amount of 4EBP-1 protein. A decreased level of
protein can be caused by enhanced degradation or re-
duced transcription and translation, respectively. The ex-
pression of 4EBP-1 was shown to be positively regulated
by transcription factor ATF-4, which is activated by JNK
signaling in murine pancreatic beta-cells [24]. Further-
more, JNK is a mitogen activated protein kinase and there-
fore member of a complex cascade [25]. An effect of
PDA-66 on one of these proteins might also influence the
activation of ATF-4 and hence 4EBP-1 expression. Never-
theless, there is a probable influence of PDA-66 on other
enzymes and cascades.
Although there was no influence on GSK3β detectable,
we hypothesized that the application of PDA-66 could
nevertheless induce comparable antiproliferative effects
in ALL cancer cells as SB-216763 due to the similar
basic molecular structure. Notably, PDA-66 treated ALL
cells showed a significant decrease in cell count and
metabolic activity which was more distinct than results
obtained in standard reference experiments with SB-
216763 (data not shown). Furthermore the treatment
with PDA-66 led to morphological changes like conden-
sation of chromatin and karyorrhexis which can be at-
tributed to the detected induction of apoptosis as well as
cell cycle alterations.
Our studies indicate different influences on cell cycle
in the analyzed ALL cell lines after 48 h incubation with
PDA-66. Concentrations of 0.25 and 0.5 μM PDA-66 led
to an increase of cells in the G0/G1 phase whereas treat-
ment with 1 μM was followed by decrease of G0/G1
phase and a significant increase in G2 phase in RS4;11
and MOLT4 cells. Jurkat cells also showed a decreasing
amount of cells in G0/G1 phase, whereas an increase
was detected in SEM cells after incubation with 0.5 μM
PDA-66. In a previous joint study presented by Eisenlöffel
et al. it could be displayed that PDA-66 treatment at
comparable concentrations as used in these analyses leads
to mitotic arrest in the G2/M phase in hNPCs [15]. This
effect on cell cycle was caused by inhibition of microtubule
polymerization [15]. Treatment of hNPCs with PDA-66
also led to an attenuated proliferation and an increased rate
of apoptosis [15]. An antiproliferative effect was alsodemonstrated in human cell lines of lung cancer and glio-
blastoma [15]. Similar results were obtained in our study.
The analyzed ALL cells showed a significant increase of
apoptosis 48 h after treatment with PDA-66.
Conclusion
We demonstrated for the first time a significant and
pronounced antiproliferative influence of PDA-66 on
ALL cells. In addition, we showed an induction of apop-
tosis via cleavage of caspases as well as suppression of
metabolic activity. While there was an effect on cell
cycle progression, no influence on the Wnt/β-catenin
signaling pathway was observed. The investigation of en-
zyme activity of GSK3β showed a minor inhibitory effect
compared to the analogue substance SB-216763. Never-
theless, the herein observed anti-tumoral potential in
ALL and the previous seen effects in neoplastic tissues
classify PDA-66 as a promising novel therapeutic agent
candidate. Consequently, the detailed analyses of PDA-
66 mediated effects should be further elucidated and val-
idated in vivo as a base for a perspective therapeutic
consideration.
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